Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Giardiasis01:12

Giardiasis

Giardiasis is a globally prevalent intestinal infection caused by the protozoan parasite Giardia duodenalis (also known as G. lamblia or G. intestinalis). This flagellated protozoan is the most frequently identified intestinal parasite in the United States and worldwide. Transmission primarily occurs via the fecal-oral route, with infection arising from ingestion of water or food contaminated with cysts. Individuals in low-resource settings, international travelers, outdoor enthusiasts, daycare...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiome alterations during and after international travel.

Journal of travel medicine·2025
Same author

Leaders behind the launching of the international society of travel medicine, the journal of travel medicine and helping to define a new medical discipline.

Journal of travel medicine·2025
Same author

Re-visiting bismuth subsalicylate for the prevention of travellers' diarrhoea.

Journal of travel medicine·2025
Same author

Microbiota restoration therapies for recurrent <i>Clostridioides difficile</i> infection reach an important new milestone.

Therapeutic advances in gastroenterology·2024
Same author

The Importance of a Healthy Microbiome in Pregnancy and Infancy and Microbiota Treatment to Reverse Dysbiosis for Improved Health.

Antibiotics (Basel, Switzerland)·2023
Same author

The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.

Clinical microbiology reviews·2023

Related Experiment Video

Updated: Jun 2, 2026

A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.
06:55

A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.

Published on: November 7, 2018

New Developments in Traveler's Diarrhea.

Javier de la Cabada Bauche1, Herbert L Dupont

  • 1Dr. de la Cabada Bauche is a Visiting Scientist at the University of Texas School of Public Health in Houston, Texas.

Gastroenterology & Hepatology
|April 9, 2011
PubMed
Summary

Traveler's diarrhea (TD) affects millions, often caused by bacteria like E. coli. Prevention and self-treatment options like antibiotics and vaccines are crucial for managing this common travel illness.

Keywords:
Traveler's diarrheaazithromycinenterotoxigenic Escherichia coliirritable bowel syndromerifaximin

More Related Videos

Epithelial Cell Infection Analyses with Shigella
04:56

Epithelial Cell Infection Analyses with Shigella

Published on: February 9, 2024

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease
03:25

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease

Published on: December 27, 2024

Related Experiment Videos

Last Updated: Jun 2, 2026

A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.
06:55

A High-throughput Platform for the Screening of Salmonella spp./Shigella spp.

Published on: November 7, 2018

Epithelial Cell Infection Analyses with Shigella
04:56

Epithelial Cell Infection Analyses with Shigella

Published on: February 9, 2024

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease
03:25

Ginger Moxibustion, A Non-pharmacological Treatment, for Diarrhea in Patients with Chronic Obstructive Pulmonary Disease

Published on: December 27, 2024

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Public Health

Background:

  • Traveler's diarrhea (TD) impacts millions globally, causing significant economic burden and disability.
  • Bacterial enteropathogens, including E. coli, Shigella, and Campylobacter, cause over 60% of TD cases.
  • Noroviruses are also a notable cause of traveler morbidity.

Purpose of the Study:

  • To review current understanding of traveler's diarrhea etiology, risk factors, and management.
  • To highlight the importance of prevention and self-treatment strategies for travelers.
  • To discuss emerging approaches in TD prevention and treatment.

Main Methods:

  • Literature review of recent studies on TD epidemiology, genetics, and treatment efficacy.
  • Analysis of common etiologic agents and their antibiotic resistance patterns.
  • Evaluation of current and developing prevention and treatment modalities.

Main Results:

  • Host genetic factors influence susceptibility to specific TD pathogens.
  • Rifaximin offers protection for short trips; vaccines are under development.
  • Effective self-treatment agents include ciprofloxacin, levofloxacin, rifaximin, and azithromycin, varying by destination.

Conclusions:

  • TD remains a significant health concern for travelers, necessitating robust prevention strategies.
  • Understanding evolving etiologic agents and resistance patterns is vital for future management.
  • New prevention and treatment approaches are expected to alter TD epidemiology in the coming decade.